Other languages Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
19.75 ^CAD	+0.61%		+0.41%	-6.62%

06-08	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
06-07	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top law firms in US opioid lawsuits to get hundreds of millions in fees	06-07
J&J-backed Rapport Therapeutics shares debut nearly 6% higher	06-07
J&J : la FDA approuve VELYS dans l'arthroplastie du genou	06-07
AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07
J&J-backed Rapport Therapeutics raises $136 mln in US IPO	06-06
Borsa di Italia: Verso l'infinito e oltre	06-06
Bolsa de Madrid: Hasta el infinito y más allá	06-06
J&J : sollicite la FDA une indiation élargie du Prezcobix	06-05
J&J : essai concluant pour Carvykti dans le myélome multiple	06-04
J&J : essai prometteur pour Tecvayli dans le myélome multiple	06-04
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	06-04
Borsa di Italia: Mai contenti!	06-04
J&J must pay $260 million in latest talc trial, Oregon jury says	06-03
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	06-03
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	06-03
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	06-03
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	06-03
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	06-03
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	06-03
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	06-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm